 For the first 2 cohorts a 15 study design will be utilized. A single patient will be enrolled sequentially into cohort 1 and cohort 2. If either patient in cohort 1 or 2 experiences a dose limiting toxicity DLT during Cycle 1, then the cohort will be expanded to enroll additional patients up to a total of 6. 